Comparison Efficacy of Intraarticular Knee Injection in Knee Osteoarthritis With Leukocyte-rich and Leukocyte-poor Platelet-rich Plasma
Overview
- Phase
- Phase 2
- Intervention
- Leukocyte-poor platelet-rich plasma
- Conditions
- Osteo Arthritis Knee
- Sponsor
- Queen Savang Vadhana Memorial Hospital, Thailand
- Enrollment
- 93
- Locations
- 1
- Primary Endpoint
- The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
To compare the efficacy of intraarticular knee injection between leukocyte-rich and leukocyte-poor platelet-rich plasma in knee osteoarthritis treatment
Detailed Description
Participants were randomized into 3 groups (leukocyte-rich platelet-rich plasma (LR-PRP), leukocyte-poor platelet-rich plasma (LP-PRP), and Corticosteroid (CS)). The primary outcome of this study is The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and was measured pre-treatment and post-treatment at follow-up at 1, 3, and 6 months
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age greater than or equal to 50 years old, Plain radiographs knee AP shows Kellgren-Lawrence classification 1-4, Refuse the use of NSAIDs for 2 weeks.
Exclusion Criteria
- •Previous intra-articular injection therapy in the past 6 months; 2) Previously treated with intra-knee PRP injection; 3) History of knee arthritis from other causes such as rheumatoid arthritis, pseudogout or infectious joints 4) History of blood disorder including anemia and thrombocytopenia (Hb \< 12 g/dl, plt \< 150,000/ml ) 5) History of surgery on the aforementioned knee 6) Obvious knee deformity (valgus \> 15, varus \> 20, flexion ROM \< 90 , extension lag \> 20) 7) Pregnancy and lactation
Arms & Interventions
Leukocyte-rich platelet-rich plasma
Leukocyte-rich PRP: Centrifuge at 300 G for 5 min, separate the plasma and buffy coat layers, and then centrifuge at 700 G for 17 min with calcium chloride at the ratio of 1:5 to PRP by volume.
Intervention: Leukocyte-poor platelet-rich plasma
Leukocyte-rich platelet-rich plasma
Leukocyte-rich PRP: Centrifuge at 300 G for 5 min, separate the plasma and buffy coat layers, and then centrifuge at 700 G for 17 min with calcium chloride at the ratio of 1:5 to PRP by volume.
Intervention: Corticosteroid
Leukocyte-poor platelet-rich plasma
Leukocyte-poor PRP: Centrifuge at 123 G for 15 min, separate the plasma and buffy coat layers, and then centrifuge at 448 G for 10 min. Calcium chloride was added 1:5 to PRP by volume.
Intervention: Leukocyte-rich platelet-rich plasma
Leukocyte-poor platelet-rich plasma
Leukocyte-poor PRP: Centrifuge at 123 G for 15 min, separate the plasma and buffy coat layers, and then centrifuge at 448 G for 10 min. Calcium chloride was added 1:5 to PRP by volume.
Intervention: Corticosteroid
Corticosteroid
Corticosteroid: 1 ml of triamcinolone acetonide (40mg/ml) mixed with 0.9% NaCl to a total volume of 4 ml.
Intervention: Leukocyte-rich platelet-rich plasma
Corticosteroid
Corticosteroid: 1 ml of triamcinolone acetonide (40mg/ml) mixed with 0.9% NaCl to a total volume of 4 ml.
Intervention: Leukocyte-poor platelet-rich plasma
Outcomes
Primary Outcomes
The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Time Frame: 6 months
a self-administered questionnaire consisting of 24 items divided into 3 subscales Pain (5 items) Stiffness (2 items) Physical Function (17 items)
Secondary Outcomes
- the time up and go test(6 months)
- 30-second chair stand test(6 months)
- VAS pain(6 months)